NYU Langone, Dana-Farber deploy oncology decision support platform

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Dana-Farber Cancer Institute’s Department of Pathology, in collaboration with Brigham and Women’s Hospital, has received renewed funding for the Ruth L. Kirschstein NRSA Institutional Research Training Grant from the NCI, providing resources for pathology residents, clinical fellows, and PhD-trained scientists pursuing research careers in cancer pathology.

August 07, 2026

Vol.52 No.31

Clinical Roundup

NYU Langone study sheds light on early respiratory failure in AML

A study led by researchers at NYU Langone Health shows how blood cancer cells enter the lungs, damage tissue, and cause severe breathing problems.

July 02, 2026

Vol.52 No.26

In Brief

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

Dana-Farber Cancer Institute announced the name of its 300-bed, freestanding cancer hospital, which is now under construction and will span 450,000 square feet across 10 inpatient floors: the Lavine Bekenstein Cancer Hospital. The building is expected to open in 2031.

June 26, 2026

Vol.52 No.25

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Monica Baskin named interim director of VCU Massey Comprehensive Cancer Center

Monica L. Baskin was named interim director of the Virginia Commonwealth University Massey Comprehensive Cancer Center.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, according to a study led by NYU Langone Health, its Perlmutter Cancer Center, and its Center for the Investigation of Environmental Hazards.

February 27, 2026

Vol.52 No.08

NYU Langone, Dana-Farber deploy oncology decision support platform

YOU MAY BE INTERESTED IN

Dana-Farber Department of Pathology receives $2.8M grant from NCI

NYU Langone study sheds light on early respiratory failure in AML

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Monica Baskin named interim director of VCU Massey Comprehensive Cancer Center

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Renew today!

Subscriber content

Never miss an issue!

Login

NYU Langone, Dana-Farber deploy oncology decision support platform

YOU MAY BE INTERESTED IN

Dana-Farber Department of Pathology receives $2.8M grant from NCI

NYU Langone study sheds light on early respiratory failure in AML

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Monica Baskin named interim director of VCU Massey Comprehensive Cancer Center

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”